^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | balstilimab (AGEN2034) (PD1 inhibitor) + zalifrelimab (UGN-301) (CTLA4 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Published date:
03/12/2020
Excerpt:
Agenus Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination with zalifrelimab [CTLA-4] for the treatment of patients with relapsed or refractory metastatic cervical cancer.
